These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1254 related articles for article (PubMed ID: 24627974)

  • 21. Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study.
    Søndergaard NR; Nørøxe KB; Carlsen AH; Randing SH; Warrer P; Thomsen PH; Clausen L
    J Child Adolesc Psychopharmacol; 2024 Apr; 34(3):137-147. PubMed ID: 38608011
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.
    Joseph A; Ayyagari R; Xie M; Cai S; Xie J; Huss M; Sikirica V
    Eur Child Adolesc Psychiatry; 2017 Aug; 26(8):875-897. PubMed ID: 28258319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
    Zimovetz EA; Beard SM; Hodgkins P; Bischof M; Mauskopf JA; Setyawan J
    CNS Drugs; 2016 Oct; 30(10):985-96. PubMed ID: 27530525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.
    Setyawan J; Guérin A; Hodgkins P; Gauthier G; Cloutier M; Wu E; Erder MH
    J Med Econ; 2013 Nov; 16(11):1275-89. PubMed ID: 24004347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
    Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
    CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].
    Häge A; Banaschewski T; Dittmann RW
    Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
    Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
    Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
    Schein J; Cloutier M; Gauthier-Loiselle M; Catillon M; Xu C; Chan D; Childress A
    J Manag Care Spec Pharm; 2024 Jun; 30(6):528-540. PubMed ID: 38824626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe.
    Siffel C; Page M; Maxwell T; Thun B; Kolb N; Rosenlund M; von Bredow D; Keja J
    J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):439-447. PubMed ID: 32315539
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T; Dirks B; Adeyi B; Scheckner B
    BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response.
    Grebla R; Setyawan J; Park C; Richards KM; Nwokeji ED; Pawaskar M; Haim Erder M; Lawson KA
    J Med Econ; 2019 Aug; 22(8):788-797. PubMed ID: 30983465
    [No Abstract]   [Full Text] [Related]  

  • 36. Post hoc analyses of response rates to pharmacological treatments in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill DR; Newcorn JH; Chen J; Werner-Kiechle T; Banaschewski T
    J Psychopharmacol; 2020 Aug; 34(8):874-882. PubMed ID: 32043417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.
    Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu EQ; Erder MH
    J Med Econ; 2013 Jul; 16(7):962-75. PubMed ID: 23621503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Mattingly GW; Weisler RH; Young J; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Goodman DW
    BMC Psychiatry; 2013 Jan; 13():39. PubMed ID: 23356790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.